ALNY Alnylam Pharmaceuticals Inc

  1. Stocks
  2. Healthcare
  3. NASDAQ: ALNY

Price (delayed)

$288.18

Market cap

$38.48B

P/E Ratio

66.1

Dividend/share

N/A

EPS

$4.36

Enterprise value

$39.74B

?
Relative Growth: Rel. Growth: 96
Relative Strength: Rel. Strength: 21
Relative Valuation: Rel. Valuation: 43
Relative Profitability: Rel. Profitability: 98

Alnylam Pharmaceuticals Inc. is a biopharmaceutical company focused on the discovery, development and commercialization of RNA interference therapeutics for genetically defined diseases. The company was founded in 2002 and is ...

Highlights
The company's net income has surged by 84% QoQ
The company's revenue has surged by 83% YoY and by 15% QoQ
The company's gross margin fell by 6% YoY
Sector: Healthcare
Industry: Biotechnology
Website: https://www.alnylam.com/
Peers: ARWR REGN SRPT OPK

Key stats

What are the main financial stats of ALNY

ALNY stock price

How has the Alnylam Pharmaceuticals stock price performed over time
Intraday
0.62%
1 week
2.23%
1 month
-3.12%
1 year
-7.97%
YTD
-27.53%
QTD
-12.9%

Financial performance

How have Alnylam Pharmaceuticals's revenue and profit performed over time
Revenue
$4.29B
Gross profit
$3.46B
Operating income
$752.14M
Net income
$577.22M
Gross margin
80.8%
Net margin
13.5%
The company's net income has surged by 84% QoQ
The company's revenue has surged by 83% YoY and by 15% QoQ
The gross profit has soared by 72% YoY and by 14% from the previous quarter
The net margin has soared by 61% from the previous quarter

Price vs fundamentals

How does ALNY's price correlate with its fundamentals

Growth

What is Alnylam Pharmaceuticals's growth rate over time

Valuation

What is Alnylam Pharmaceuticals stock price valuation
P/E
66.1
P/B
35.54
P/S
8.93
EV/EBIT
45.69
EV/EBITDA
42.98
EV/Sales
9.27
ALNY's EPS has surged by 82% since the previous quarter
ALNY's price to book (P/B) is 73% less than its last 4 quarters average of 133.2
The equity has grown by 36% from the previous quarter
The company's revenue has surged by 83% YoY and by 15% QoQ
ALNY's price to sales (P/S) is 52% lower than its 5-year quarterly average of 18.7 and 41% lower than its last 4 quarters average of 15.1

Efficiency

How efficient is Alnylam Pharmaceuticals business performance
The ROE has soared by 123% YoY and by 9% from the previous quarter
The return on assets has surged by 76% since the previous quarter
ALNY's return on invested capital has surged by 52% since the previous quarter
ALNY's return on sales is up by 31% since the previous quarter

Dividends

What is ALNY's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for ALNY.

Financial health

How did Alnylam Pharmaceuticals financials performed over time
The total assets is 27% more than the total liabilities
The total assets has increased by 22% YoY and by 3.3% from the previous quarter
The company's quick ratio rose by 15% QoQ
The debt is 176% more than the equity
Alnylam Pharmaceuticals's debt to equity has plunged by 90% YoY and by 27% from the previous quarter
The equity has grown by 36% from the previous quarter

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.